The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis
Open accessAbstract
In the United States, approximately 35% of adults with Systemic Lupus Erythematosus (SLE) have clinical evidence of nephritis at the time of diagnosis; with an estimated total of 50–60% developing nephritis during the first 10 years of disease [1–4]. The prevalence of nephritis is significantly higher in African Americans and Hispanics than in Caucasians, and is higher in men than in women. Renal damage is more likely to develop in non-Caucasian groups [2–4]. Overall survival in patients with SLE is approximately 95% at 5 years after diagnosis and 92% at 10 years [5, 6]. The presence of lupus nephritis significantly reduces survival, to approximately 88% at 10 years, with even lower survival in African Americans [5, 6]. The American College of Rheumatology (ACR) last published guidelines for management of systemic lupus erythematosus (SLE) in 1999 [7]. That publication was designed primarily for education of primary care physicians and recommended therapeutic and management approaches for many manifestations of SLE. Recommendations for management of lupus nephritis (LN) consisted of pulse glucocorticoids followed by high dose daily glucocorticoids in addition to an immunosuppressive medication, with cyclophosphamide viewed as the most effective immunosuppressive medication for diffuse proliferative glomerulonephritis. Mycophenolate mofetil was not yet in use for lupus nephritis and was not mentioned. Since that time, many clinical trials of glucocorticoids-plus-immunosuppressive interventions have been published, some of which are high quality prospective trials, and some not only prospective but also randomized. Thus, the ACR determined that a new set of management recommendations was in order. A combination of extensive literature review and the opinions of highly qualified experts, including rheumatologists, nephrologists and pathologists, has been used to reach the recommendations. The management strategies discussed here apply to lupus nephritis in adults, particularly to those receiving care in the United States of America, and include interventions that were available in the United States as of April 2011. While these recommendations were developed using rigorous methodology, guidelines do have inherent limitations in informing individual patient care; hence the selection of the term “recommendations.” While they should not supplant clinical judgment or limit clinical judgment, they do provide expert advice to the practicing physician managing patients with lupus nephritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Hunt, S. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.022 · Cited by 4,154
WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.167586 · Cited by 2,251
(2001) · Defense Technical Information Center (DTIC) · Cited by 2,158
Navarra, S. V., Guzmán, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. K.-M., Thomas, M., Kim, H.-Y., León, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,074
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
Weening, J. J., D’Agati, V. D., Schwartz, M. M., Seshan, S. V., Alpers, C. E., Appel, G. B., Balow, J. E., Bruijn, J. A., Cook, T., Ferrario, F., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000108969.21691.5d · Cited by 2,008
Singh, J. A., Furst, D. E., Bharat, A., Curtis, J. R., Kavanaugh, A. F., Kremer, J. M., Moreland, L. W., O'Dell, J., Winthrop, K. L., Beukelman, T., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21641 · Cited by 1,789
Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D. J., Tegzová, D., Sanchez-Guerrero, J., Schwarting, A., Merrill, J. T., Chatham, W. W., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30613 · Cited by 1,683
Self-citationThe classification of glomerulonephritis in systemic lupus erythematosus revisited
Weening, J. J., ON Behalf of the International Society of Nephrology and Renal Pathology Society Working Group on the Classification Oflupus Nephritis, D'agati, V. D., Schwartz, M. M., Seshan, S. V., Alpers, C. E., Appel, G. B., Balow, J. E., Bruijn, J. A. N. A., Cook, T., et al. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00443.x · Cited by 1,652
Merrill, J. T., Neuwelt, C. M., Wallace, D. J., Shanahan, J. C., Latinis, K. M., Oates, J. C., Utset, T. O., Gordon, C., Isenberg, D. A., Hsieh, H., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27233 · Cited by 1,409
Self-citationCervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Mejía, J. C., Aydintug, A. O., Chwalinska-Sadowska, H., de Ramón, E., et al. (2003) · Medicine · doi:10.1097/01.md.0000091181.93122.55 · Cited by 1,377
Renal-Limited “Lupus-Like” Nephritis: How Much of a Lupus
Maziad, A. S. A., Torrealba, J., Seikaly, M. G., Hassler, J. R., & Hendricks, A. R. (2017) · Case Reports in Nephrology and Dialysis · doi:10.1159/000475493 · Cited by 1,299
Austin, H. A., Klippel, J. H., Balow, J. E., Le Riche, N. G. H., Steinberg, A. D., Plotz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,185
Mortality in systemic lupus erythematosus
Bernatsky, S., Boivin, J. ‐., Joseph, L., Manzi, S., Ginzler, E., Gladman, D. D., Urowitz, M., Fortin, P. R., Petri, M., Barr, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21955 · Cited by 1,181
Self-citationSaag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins‐Melton, M., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.23721 · Cited by 1,157
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Ginzler, E. M., Dooley, M. A., Aranow, C., Kim, M. Y., Buyon, J., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043731 · Cited by 1,128
Self-citationMycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Isenberg, D., Jayne, D., Li, L.-S., Mysler, E., Sa[Combining Acute Accent]nchez-Guerrero, J., Solomons, N., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008101028 · Cited by 1,118
Houssiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., Garrido, E. D. R., Danieli, M. G., Abramovicz, D., Blockmans, D., Mathieu, A., Direskeneli, H., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10461 · Cited by 1,077
Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M. A. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101766 · Cited by 978
Agodoa, L. Y. (2001) · JAMA · doi:10.1001/jama.285.21.2719 · Cited by 944
Recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis
American College of Rheumatology task force on Osteoporosis guidelines (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391104 · Cited by 848
Sequential Therapies for Proliferative Lupus Nephritis
Contreras, G., Pardo, V., Leclercq, B., Lenz, O., Tozman, E., O'Nan, P., & Roth, D. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031855 · Cited by 818
Kunz, R., Friedrich, C., Wolbers, M., & Mann, J. F. E. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-1-200801010-00190 · Cited by 717
Grossman, J. M., Gordon, R., Ranganath, V. K., Deal, C., Caplan, L., Chen, W., Curtis, J. R., Furst, D. E., McMahon, M., Patkar, N. M., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20295 · Cited by 708
Self-citation(1991) · New England Journal of Medicine · doi:10.1056/nejm199101173240303 · Cited by 677
Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis
Dooley, M. A., Jayne, D., Ginzler, E. M., Isenberg, D., Olsen, N. J., Wofsy, D., Eitner, F., Appel, G. B., Contreras, G., Lisk, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014460 · Cited by 642
Gourley, M. F., Austin III, H. A., Scott, D., Yarboro, C. H., Vaughan, E. M., Muir, J., Boumpas, D. T., Klippel, J. H., Balow, J. E., & Steinberg, A. D. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00003 · Cited by 607
Houssiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., de Ramon Garrido, E., Danieli, M. G., Abramovicz, D., Blockmans, D., Cauli, A., Direskeneli, H., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.102533 · Cited by 542
Hydroxychloroquine in lupus pregnancy
Clowse, M. E. B., Magder, L., Witter, F., & Petri, M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22159 · Cited by 529
Boumpas, D. T., Austin, H. A., Vaughan, E. M., Yarboro, C. H., Klippel, J. H., & Balow, J. E. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-5-199309010-00003 · Cited by 500
Houssiau, F. A., D'Cruz, D., Sangle, S., Remy, P., Vasconcelos, C., Petrovic, R., Fiehn, C., de Ramon Garrido, E., Gilboe, I.-M., Tektonidou, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.131995 · Cited by 499
Illei, G. G., Austin, H. A., Crane, M., Collins, L., Gourley, M. F., Yarboro, C. H., Vaughan, E. M., Kuroiwa, T., Danning, C. L., Steinberg, A. D., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-4-200108210-00009 · Cited by 492
Chan, T.-M., Tse, K.-C., Tang, C. S.-O., Mok, M.-Y., & Li, F.-K. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080686 · Cited by 479
Terrier, B., Amoura, Z., Ravaud, P., Hachulla, E., Jouenne, R., Combe, B., Bonnet, C., Cacoub, P., Cantagrel, A., De Bandt, M., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27541 · Cited by 411
Houssiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., de Ramon Garrido, E., Danieli, M. G., Abramovicz, D., Blockmans, D., Mathieu, A., Direskeneli, H., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20666 · Cited by 391
Fessler, B. J., Alarcón, G. S., McGwin, G., Roseman, J., Bastian, H. M., Friedman, A. W., Baethge, B. A., Vilá, L., Reveille, J. D., & for the LUMINA Study Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.21039 · Cited by 377
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study
Isenberg, D., Appel, G. B., Contreras, G., Dooley, M. A., Ginzler, E. M., Jayne, D., Sánchez-Guerrero, J., Wofsy, D., Yu, X., & Solomons, N. (2010) · Rheumatology · doi:10.1093/rheumatology/kep346 · Cited by 356
Steinberg, A. D., & Steinberg, S. C. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780340803 · Cited by 348
Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans
Dooley, M. A., Hogan, S., Jennette, C., Falk, R., & for the Glomerular Disease Collaborative Network (1997) · Kidney International · doi:10.1038/ki.1997.162 · Cited by 341
Pons‐Estel, G. J., Alarcón, G. S., McGwin, G., Danila, M. I., Zhang, J., Bastian, H. M., Reveille, J. D., & Vilá, L. M. (2009) · Arthritis Care & Research · doi:10.1002/art.24538 · Cited by 306
Successful Treatment of Class V+IV Lupus Nephritis with Multitarget Therapy
Bao, H., Liu, Z.-H., Xie, H.-L., Hu, W.-X., Zhang, H.-T., & Li, L.-S. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007121272 · Cited by 301
Jung, H., Bobba, R., Su, J., Shariati‐Sarabi, Z., Gladman, D. D., Urowitz, M., Lou, W., & Fortin, P. R. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27289 · Cited by 291
Somers, E. C., Marder, W., Christman, G. M., Ognenovski, V., & McCune, W. J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21263 · Cited by 269
Guidelines for referral and management of systemic lupus erythematosus in adults
(1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199909)42:9<1785::aid-anr1>3.0.co;2-# · Cited by 269
ONG, L. M., HOOI, L. S., LIM, T. O., GOH, B. L., AHMAD, G., GHAZALLI, R., TEO, S. M., WONG, H. S., TAN, S. Y., SHAARIAH, W., et al. (2005) · Nephrology · doi:10.1111/j.1440-1797.2005.00444.x · Cited by 252
Kaiser, R., Cleveland, C. M., & Criswell, L. A. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.093013 · Cited by 244
Grootscholten, C., Erythematosus, F. T. D. W. P. O. S. L., Ligtenberg, G., Hagen, E. C., van den Wall Bake, A. W. L., de Glas-Vos, J. W., Bijl, M., Assmann, K. J., Bruijn, J. A., Weening, J. J., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5001630 · Cited by 237
Costenbader, K. H., Desai, A., Alarcón, G. S., Hiraki, L. T., Shaykevich, T., Brookhart, M. A., Massarotti, E., Lu, B., Solomon, D. H., & Winkelmayer, W. C. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30293 · Cited by 230
Baseline characteristics of a multiethnic lupus cohort: PROFILE
Alarcon, G. S., McGwin, G., Petri, M., Reveille, J. D., Ramsey-Goldman, R., Kimberly, R. P., & the PROFILE Study Group (2002) · Lupus · doi:10.1191/0961203302lu155oa · Cited by 214
Self-citationRadhakrishnan, J., Moutzouris, D.-A., Ginzler, E. M., Solomons, N., Siempos, I. I., & Appel, G. B. (2010) · Kidney International · doi:10.1038/ki.2009.412 · Cited by 207
Chen, W., Tang, X., Liu, Q., Chen, W., Fu, P., Liu, F., Liao, Y., Yang, Z., Zhang, J., Chen, J., et al. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.08.036 · Cited by 202
Self-citationMoroni, G., Doria, A., Mosca, M., Alberighi, O. D. C., Ferraccioli, G., Todesco, S., Manno, C., Altieri, P., Ferrara, R., Greco, S., et al. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02271205 · Cited by 175
Mortality Risks Associated With Specific Clinical Manifestations of Systemic Lupus Erythematosus
Ward, M. M. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.12.1337 · Cited by 174
Smith, S. C., Jr. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/0pvp-z731 · Cited by 159
Baseline characteristics of a multiethnic lupus cohort: PROFILE
Gs, A., McGwin, G., Petri, M., et al. (2002) · Lupus · doi:10.1191/9612332lu155oa · Cited by 153
Belimumab for Systemic Lupus Erythematosus
Hahn, B. H. (2013) · New England Journal of Medicine · doi:10.1056/nejmct1207259 · Cited by 150
Self-citationMiyasaka, N., Kawai, S., & Hashimoto, H. (2009) · Modern Rheumatology · doi:10.1007/s10165-009-0218-5 · Cited by 128
Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?
Wallace, D. J. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780301219 · Cited by 124
Self-citationTouma, Z., Gladman, D. D., Urowitz, M. B., Beyene, J., Uleryk, E. M., & Shah, P. S. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.100130 · Cited by 119
Sinclair, A., Appel, G. B., Dooley, M. A., Ginzler, E. M., Isenberg, D. A., Jayne, D. R. W., Wofsy, D., & Solomons, N. (2007) · Lupus · doi:10.1177/0961203307084712 · Cited by 117
McMahon, M. A., Hahn, B. H., & Skaggs, B. J. (2011) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.98 · Cited by 117
Self-citationGrootscholten, C., Bajema, I. M., Florquin, S., Steenbergen, E. J., Peutz‐Kootstra, C. J., Goldschmeding, R., Bijl, M., Hagen, E. C., van Houwelingen, H. C., Derksen, R. H. W. M., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22449 · Cited by 99
Review of ACR renal criteria in systemic lupus erythematosus
Dooley, M. A., Aranow, C. B., & Ginzler, E. M. (2004) · Lupus · doi:10.1191/0961203304lu2023oa · Cited by 94
Dall’Era, M., Stone, D., Levesque, V., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20397 · Cited by 92
Changes in the Incidence of End-stage Renal Disease Due to Lupus Nephritis, 1982-1995
Ward, M. M. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.20.3136 · Cited by 92
Pregnancy and autoimmune diseases
Gordon, C. (2004) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2004.02.012 · Cited by 88
Rituximab Therapy in Lupus Nephritis: Current Clinical Evidence
Ramos‐Casals, M., Díaz‐Lagares, C., Cárdenas, M. J. S., Brito‐Zerón, P., Cuadrado, M. J., Sanna, G., Bertolaccini, M. L., & Khamashta, M. A. (2010) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8205-3 · Cited by 46
Hardinger, K. L., Hebbar, S., Bloomer, T., & Murillo, D. (2008) · Clinical Transplantation · doi:10.1111/j.1399-0012.2008.00820.x · Cited by 26
Drug Monitoring in Systemic Lupus Erythematosus: A Systematic Review
Schmajuk, G., & Yazdany, J. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2010.07.010 · Cited by 12
Self-citation
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Tashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,078
Self-citationTwo-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Furie, R., Rovin, B. H., Houssiau, F., Malvar, A., Teng, Y. K. O., Contreras, G., Amoura, Z., Yu, X., Mok, C.-C., Santiago, M. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001180 · Cited by 1,032
Anders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
Kiriakidou, M., & Ching, C. L. (2020) · Annals of Internal Medicine · doi:10.7326/aitc202006020 · Cited by 821
Metadata
- Authors
- Hahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., Ramsey‐Goldman, R., Singh, K., Khalighi, M., Choi, S., Gogia, M., Kafaja, S., Kamgar, M., Lau, C., Martin, W. J., Parikh, S., Peng, J., Rastogi, A., Chen, W., & Grossman, J. M.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2012-05-03
- Volume
- 64
- Issue
- 6
- Pages
- 797-808
- ISSN
- 0893-7524 (ISSN-L)
- 2151-464X
- 2151-4658
- OpenAlex
- W1963756694
- Cited by
- 1,463
- References
- 70
- FWCI
- 64.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.